FDA Reviews Corcept’s NDA for Relacorilant in Drug-Resistant Ovarian Cancer
Sept 10 (Reuters) - Corcept Therapeutics Inc CORT.O:
FDA FILES CORCEPT’S NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
CORCEPT THERAPEUTICS INC - FDA ASSIGNS PDUFA DATE OF JULY 11, 2026 FOR RELACORILANT
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







